Y. Sakurai

Dermatological side‐effects of telaprevir‐based triple therapy for chronic hepatitis C in phase III trials in Japan

M. Ohtsuki, H. Sueki, H. Kumada, 2013, The Journal of dermatology.

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

H. Kumada, M. Kano, F. Suzuki, 2012, Journal of viral hepatitis.